US › Healthcare

BioLineRx Ltd (BLRX)

US · Healthcare · Biotechnology

$2.53+2.02%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$299,048

Revenue YoY

-1.6%

Net profit

$-3.1M

EPS

$-0.77

EPS estimate

$-0.30

Net margin

-1,029.3%

EPS came in at -0.77 against a street estimate of -0.30 — a miss of 156.7%.

Key statistics

Market cap

$11.0M

P/E

0.0

Forward P/E

93.5

P/B

0.88

Book value

$3.00

EPS (TTM)

$0.00

52-week high

$4.56

52-week low

$2.15

50-day MA

$2.80

200-day MA

$2.88

Beta

0.69

Analyst view

Analysts rate BioLineRx Ltd a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $22.00.

Shareholding

Insiders

3.52%

Institutions

1.37%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.31%
XTX Topco Ltd	0.23%
Rhumbline Advisers	0.05%
BNP Paribas Arbitrage, SA	0.04%
Wells Fargo & Co	0.04%
Citigroup Inc	0.04%
UBS Group AG	0.01%
Banque Cantonale Vaudoise	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioLineRx Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.